Diagnostic Utility of Peritoneal and Ovarian Fluid LDH and Cholesterol in Cystic Ovarian Tumours
DOI:
https://doi.org/10.21276/apalm.3837Keywords:
ovarian neoplasms, ovarian fluid, peritoneal fluid, biochemical, LDH, cholesterolAbstract
Background: Ovarian cancer is the third most common cancer in Indian women. Biochemical analysis of ovarian and peritoneal fluid, especially lactate dehydrogenase (LDH) and cholesterol level is shown to be elevated in cases of malignancy. Peritoneal fluid LDH levels were also found to be of prognostic significance. To assess the diagnostic utility of LDH and cholesterol levels of ovarian cyst fluid and peritoneal fluid in cystic ovarian neoplasms by correlating with histopathological examination.
Material and Methods: Prospective cohort study carried out in a tertiary care hospital. Ovarian cyst fluid and/or peritoneal fluid in resected ovarian neoplasms were processed on automated biochemistry analyzers.
Results: Seventy-nine ovarian neoplasms with their corresponding ovarian cyst fluid and/or peritoneal fluid were studied. The accuracy rate for diagnosis of malignant tumors by ovarian fluid LDH and cholesterol levels was found to be 100% and 90.14% respectively, while that of peritoneal fluid LDH and cholesterol levels was 88.88% and 80.55% respectively.
Conclusion: Biochemical analysis (LDH and cholesterol) of peritoneal fluid can be used in pre-operative and post-operative management of ovarian malignancy. Ovarian fluid LDH was the most sensitive and specific parameter followed by peritoneal fluid LDH for differentiating ovarian malignancy from benign ovarian tumors.
References
1. Kancherla J, Kalahasti R, Sekhar KPAC, Yarlagadda SB, Devi SP. Histomorphological Study of Ovarian Tumors: An Institutional Experience of 2 Years. Int J Sci Stud 2017;5(3):232-235.
2. Population fact sheet – India. [December 2020] The global cancer observatory, International Agency for Research on Cancer, World Health Organisation. Retrieved from 356-india-fact-sheets.pdf (iarc.fr)
3. Yemelyanova AV, Vang, Judson K et al. Distinction of Primary and metastatic tumours involving the ovary. Am J Surg Pathol 2008;32(1):128-38.
4. Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A, Siegel RL. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018 Jul;68(4):284-296. doi: 10.3322/caac.21456. Epub 2018 May 29. PMID: 29809280; PMCID: PMC6621554.
5. Lee JY, Kim S, Kim YT et al. Changes in ovarian cancer survival during the 20 years before the era of targeted therapy. BMC Cancer 18, 601 (2018).
6. Khanna M, Sharma M, Manjari M, Madan M, Kaur K, Gupta S. Utility of Image Guided Fine needle aspiration in the Diagnosis Of Ovarian Masses: A Cytohistopathological Correlation. Annals of Pathology and Laboratory Medicine. 2016 Dec 12;3(06).
7. Cancer Facts & Figures 2023, American Cancer Society. Retrieved from https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2023/2023-cancer-facts-and-figures.pdf
8. Ahmed N, Stenvers K. Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research. Frontiers in oncology. 2013 Sep 25;3:256.
9. Boran N, Kayikcioglu F, Yalvac S, Tulunay G, Ekinci U, Kose MF. Significance of serum and peritoneal fluid lactate dehydrogenase levels in ovarian cancer. Gynecologic and obstetric investigation 2000;49(4):272-4.
10. Podzielinski I, Saunders BA, Kimbler KD, Branscum AJ, Fung ET, DePriest PD, van Nagell JR, Ueland FR, Baron AT. Apolipoprotein concentrations are elevated in malignant ovarian cyst fluids suggesting that lipoprotein metabolism is dysregulated in epithelial ovarian cancer. Cancer Invest. 2013 May;31(4):258-72. doi: 10.3109/07357907.2013.789896. PMID: 23627408.
11. Anton C. Research Project Evaluation of a new combination of tumor markers in the differential diagnoses of ovarian cysts. Person responsible for the project and Advisor: Prof. Jesus Paula Carvalho Associate Professor and Responsible for Female Genital Oncology Group. 2021.
12. Ades A, Carvalho J, Graziani S, Amancio R, Souen J, Pinotti J, Maranhão R. Uptake of a Cholesterol-Rich Emulsion by Neoplastic Ovarian Tissues. Gynecologic oncology. 2001;82:84-7. doi: 10.1006/gyno.2001.6203.
13. Shender VO, Pavlyukov MS, Ziganshin RH, Arapidi GP, Kovalchuk SI, Anikanov NA, Altukhov IA, Alexeev DG, Butenko IO, Shavarda AL, Khomyakova EB. Proteome-metabolome profiling of ovarian cancer ascites reveals novel components involved in intercellular communication. Molecular & Cellular Proteomics. 2014 Dec 1;13(12):3558-71.
14. Matte I, Bessette P, Piche A. Ascites in ovarian cancer progression: opportunities for biomarker discovery and new avenues for targeted therapies. Ascites: Physiopathology, Treatment, Complications and Prognosis. 2017 Nov 29:145.
15. Knight JA, Wu JT, Miya T, Knight DP. Comparison of biochemical markers between benign and malignant ovarian cysts. Clin Physiol Biochem. 1986;4(2):130-5. PMID: 3516514.
16. Parker MF, Conslato SS, Chang AS, Taylor RR, Reed ME, Mayer AR. Chemical analysis of adnexal cyst fluid. Gynecol Oncol. 1999 Apr;73(1):16-20. doi: 10.1006/gyno.1998.5263. PMID: 10094874.
17. Kim S, Lee M, Dhanasekaran DN, Song YS. Activation of LXRα/β by cholesterol in malignant ascites promotes chemoresistance in ovarian cancer. BMC cancer. 2018 Dec;18(1):1-2.
18. Rana SV, Babu SG, Kocchar R. Usefulness of ascitic fluid cholesterol as a marker for malignant ascites. Medical science monitor. 2005 Mar 1;11(3):CR136-42.
19. Ekpe L, Ebughe G. Usefulness of Ascitic Fluid Cholesterol and Protein in the Differential Diagnosis of Ascites in Nigeria: Comparison with Conventional Cytology. International Journal of Tropical Disease & Health. 2015;8:25-33.
20. Mayank, Priyadarshi BP, Singh M, Verma AK, Middha T. Study the usefulness of ascitic fluid cholesterol level in diagnosis of malignant related ascites. Int J Adv Med 2018;5:400-3.
21. Gulec UK, Paydas S, Guzel AB, Buyukkurt S, Seydaoglu G, Vardar MA. Comparative analysis of CA 125, beta-2 microglobulin, lactic dehydrogenase levels in serum and peritoneal fluid in patients with ovarian neoplasia. Medical Oncology. 2012 Dec 1;29(4):2937-43.
22. Alexandrakis MG, Moschandrea JA, Koulocheri SA, Kouroumalis E, Eliopoulos GD. Discrimination between malignant and nonmalignant ascites using serum and ascetic fluid proteins in a multivariate analysis model. Digestive diseases and sciences. 2000 Mar 1;45(3):500-8.
23. Halperin R, Hada E, Bukovsky I, Schneider D. Peritoneal fluid analysis in the differentiation of ovarian cancer and benign tumor. Eur J Gynaecol Oncol. 1999;20(1):40-4.
24. Zhu H, Shen Y, Deng K, Liu X, Zhao Y, Liu T, Huang Y. Diagnostic accuracy of ascitic cholesterol concentration for malignant ascites: a meta-analysis. Int J Clin Exp Med. 2015 Oct 15;8(10):18494-9. PMID: 26770458; PMCID: PMC4694358.
25. Yüce K, Baykal C, Genç C, Al A, Ayhan A. Diagnostic and prognostic value of serum and peritoneal fluid lactate dehydrogenase in epithelial ovarian cancer. European Journal of Gynaecological Oncology. 2001;22(3):228-232.
26. Alexandrakis MG, Moschandrea JA, Koulocheri SA, Kouroumalis E, Eliopoulos GD. Discrimination between malignant and nonmalignant ascites using serum and ascetic fluid proteins in a multivariate analysis model. Digestive diseases and sciences. 2000 Mar 1;45(3):500-8.
27. Kirstjansdottir B, Levan K, Partheen K, Carlsohn E, Sundfeldt K. Potential tumour biomarkers identified in ovarian cyst fluid by quantitative proteomic analysis, iTRAQ. Clinical proteomics. 2013 Dec 1;10(1):4.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Sonali Rajesh Saraf, Riya Zambare
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).
How to Cite
